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I- Summary 
Bacitracin is a hexapeptide antibiotic, with a substituted thiazolidine nucleus, 
produced by some strains of B. licheniformis. It is mainly active against Gram-
positive bacteria, although many differences in susceptibility exist among the 
bacterial species. 
Alpharma A.S. Norway has produced bacitracin for use in human medicine since 
1954. Until 1998, the fermentation waste from the production of bacitracin was added 
to animal feed in some European countries, including Norway, to promote growth of 
pigs and domestic fowl. In 1998, fermentation waste containing bacitracin as a food 
additive was banned by the EU to reduce the risk of developing bacitracin-resistant 
bacteria in animals, and the subsequent possible transfer of such bacteria to humans 
via the food chain. Use of fermentation waste containing bacitracin as a feed additive 
has not been officially banned in Norway, but it is no longer used for this purpose. 
Alpharma is therefore actively seeking alternative uses for their production waste. As 
the waste material is rich in nutrients, the company proposes that it could be 
developed as a soil additive by fermenting it with chipped bark and lime. 
The Norwegian Food Safety Authority (Mattilsynet) commissioned the Panel on 
Biological Hazards of the Norwegian Scientific Committee for Food Safety 
(Vitenskapskomitéen for mattrygghet) to develop a risk assessment regarding the 
use of composted waste material from Alpharma’s production of bacitracin, as a soil 
additive. In response, an ad hoc Working Group of experts was appointed with the 
mandate to draft a risk assessment which should include the following elements: 
assessment of risk to human health and/or the environment in relation to residual 
content of bacitracin in the finished soil additive product and assessment of the risk in 
relation to dissemination of the production strain and antimicrobial resistance genes.  
The Panel on Biological Hazards concludes that the risks to human health and the 
environment posed by residual bacitracin present in the finished product are minimal. 
Furthermore, as Bacillus licheniformis is considered essentially non-pathogenic, 
occurring rarely as an opportunistic pathogen, the risk posed by this bacterium to 
human health or the environment is very low. It is reasonable to assume that during 
the early composting process horizontal transfer of bacitracin  and erythromycin 
resistance genes, from the B. licheniformis producer strain to environmental bacteria, 
will exceed background levels. However, this is considered to represent a low risk to 
human health and the environment.  
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II- Background 
The antibiotic bacitracin, produced by the bacterium Bacillus licheniformis, is a 
mixture of several high molecular weight polypeptides (bacitracin A, B, and C and 
several minor components). When bacitracin was introduced into human medicine for 
clinical use, it was found to be nephrotoxic, and preparations for systemic use were 
soon withdrawn. Currently, bacitracin is widely employed as a topical remedy for 
wounds or ophthalmic ointment (Phillips 1999). 
In this document the use of bacitracin as a feed additive refers to the use of the 
waste produced from bacitracin fermentation. Alpharma AS has produced bacitracin 
for use in human medicine since 1954. Until 1998, the fermentation waste from 
bacitracin production was added to animal feed in Norway and some other European 
countries to promote the growth of pigs and poultry. This practice is known to result 
in improved weight gain, and consequently less food is needed to bring the animals 
to their required slaughter weight. In 1998, bacitracin as a feed additive was banned 
by the EU to reduce the risk of developing bacitracin-resistant bacteria in animals, 
and subsequently possible transfer of such bacteria to humans via the food chain. 
Use of bacitracin as a feed additive has not been officially banned in Norway (FOR 
2005-04-12 nr. 12: Forskrift om tilsetningsstoffer til bruk i fôrvarer), but the industry 
implemented a self-imposed ban on all growth promoters in 1995, following the ban 
of avoparcin as a feed additive. Therefore bacitracin has not been used as a feed 
additive during the last ten years. Alpharma is therefore seeking alternative uses for 
their production waste. As the waste material is rich in nutrients, the company 
proposes that it could be developed as a soil additive by fermenting it with chipped 
bark and lime.  If approved by the Norwegian Food Safety Authority (Mattilsynet), the 
resulting compost, estimated to be about 1700 metric tons per year, will be sold on 
the open market. 
III- Legislation 
According to the Regulation on Fertilizer Materials of Organic Origin1: 
§9  
Import of, or trade with, products that do not fulfil the quality requirements laid down 
in this regulation is prohibited. The Norwegian Food Safety Authority can ban 
products that entail an environmental risk or can harm or affect the health of plants, 
animals or human beings.  
§10.2  
                                                 
1
  
§9  
 
Det er forbudt å importere eller omsette produkter som ikke tilfredsstiller de kvalitetskrav som går fram 
av denne forskrift. Mattilsynet kan i alle tilfelle forby produkter som kan medføre miljørisiko ved bruk, 
eller som kan skade eller redusere menneskers, dyrs eller planters helse. 
 
§10.2  
Den som produserer eller omsetter produkter etter denne forskrift skal vise aktsomhet og treffe 
rimelige tiltak for å begrense og forebygge at produktet inneholder organiske miljøgifter, 
plantevernmidler, antibiotika/kjemoterapeutika eller andre miljøfremmede organiske stoffer i mengder 
som kan medføre skade på helse eller miljø ved bruk.  
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The producer or traders must show precaution and lay down measures to prevent the 
product containing environmentally hazardous organic substances, pesticides, 
antibiotics/chemotherapeutic substances or other organic pollutants in amounts that 
pose risks to human health or to the environment when used. 
IV- Terms of reference 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomitéen for 
mattrygghet) has been commissioned by the Norwegian Food Safety Authority 
(Mattilsynet) to assess the risks of using composted waste material from Alpharma’s 
production of bacitracin as a soil additive2: 
Three questions, under two headings, of particular concern have been raised by the 
Norwegian Food Safety Authority: 
 
1- Assessment of risk in relation to residual content of bacitracin in the 
finished product. 
Will the residual content of bacitracin in the proposed compost pose any risk to 
human health or the environment? 
 
2- Assessment of risk in relation to dissemination of the production strain  
a- Assess the risks of disseminating Bacillus lichenformis 20443 to the environment, 
and whether such dissemination could pose a threat to human health or the 
environment. 
 
b- Assess the risks of dissemination of antimicrobial resistance genes from the 
compost. 
 
V- Hazard identification 
Production, handling, and application of composted waste material from the 
production of bacitracin may involve several hazards, as follows: 
• Dissemination of bacitracin 
• Dissemination and proliferation of the B. licheniformis production strain 
• Dissemination and transfer of bacitracin, sulfonamide and erythromycin 
resistance genes to animal and human pathogens 
  
                                                 
2
  
Vurdering av risiko knyttet til restinnhold av bacitracin 
Vi ber om en vurdering av om inneholdet av bacitracin i kompostenutgjør noen helse- eller miljø risiko. 
 
Vurdering av risiko knyttet til spredning av produksjonsstammen 
Vi ber om en vurdering av om spredning av Bacillus licheniformis kan spres fra komposten, og om 
dette eventuelt utgjør noen risiko for helse eller miljø, 
Vi ber om en vurdering av risiko knyttet til spredning av gen materiale som koder for 
antibiotikaresistens fra denne komposten. 
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VI- Hazard characterization 
VI-I- Bacillus licheniformis 
The B. licheniformis 20443 strain used for bacitracin production was derived from B. 
licheniformis ATCC 10716 by conventional mutagenesis and is not a product of 
recombinant DNA technology. The parent strain was originally isolated from soil and 
produced bacitracin at a lower rate. The B. licheniformis 20443 strain used by 
Alpharma is reported to be resistant to bacitracin, sulfonamides and erythromycin, 
although the method used for susceptibility testing is not according to standardized 
methodology. According to Alpharma AS, there is no information regarding the 
association between phenotypical resistance against sulfonamides and the presence 
of resistance genes. However, resistance against bacitracin and erththromycin is 
associated with the bcr gene cassette and the ermDgene, respectively (reported 
during meeting with representatives from Alpharma; 01.02.06).   
VI-I-i- Hazards to humans, animals, plants and environment 
B. licheniformis appears to have a very low degree of virulence. In general, it does 
not produce significant quantities of extracellular enzymes or other factors likely to 
enable it to cause infection. There are some reports in the literature of human 
infections with B. licheniformis, however, these have all occurred in 
immunosuppressed individuals. In order for infection with B. licheniformis to occur it 
is probable that either the infectious dose must be very high, or the immune status of 
the host must be severely reduced (Edberg 1992). However, while the likelihood of B. 
licheniformis infection in humans is low, it is not nonexistent. Toxin-producing strains 
of B. licheniformis have been obtained from foods involved in food-poisoning 
incidents, from raw milk, from industrially-produced baby food  (Salkinoja-Salonen et 
al. 1999), cooked meats, and vegetables (Rosenkvist and Hansen 1995;Tatzel et al. 
1994).  
 
There are numerous reports in the literature which associate B. licheniformis with 
livestock abortions (McClung 1992). It has been reported that B. licheniformis can be 
associated with abortions in cattle, sheep and swine (Kirkbride et al. 1986;Logan 
1988). In Norway, two cases of abortion caused by B. licheniformis in dairy cattle 
were reported in 2003 (Bergsjø 2003). It is believed that hay and silage of poor 
quality may be predisposing factors.  
 
No reports in the literature indicate that B. licheniformis is a plant pathogen. On the 
contrary, it has been reported that B. licheniformis in composting material promotes 
the growth of plants.  
 
As B. licheniformis has only infrequently been associated with infections in humans, 
antimicrobial susceptibility testing of B. licheniformis strains has gained little 
attention. The species is reported to be intrinsically intermediately resistant to 
penicillin (Coonrod et al. 1971;Weber et al. 1988). Data regarding susceptibility of B. 
licheniformis to other antimicrobial agents is sparse. 
 
In the opinion of the Scientific Committee on Animal Nutrition (SCAN), the use of 
Bacillus licheniformis NCTC 13123 in feedstuffs for pigs is considered unsafe due to 
the risk of dissemination of genes that confer resistance to clinically important 
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antimicrobials via the food chain (European Commission 2000). In reaching this 
decision, SCAN recognised that the magnitude of the risk could not currently be 
quantified, but is probably low. However given the continuing widespread use of 
macrolide antimicrobials in pig production, and the selective pressure this provides, 
SCAN decided to adopt a precautionary approach consistent with its previously 
expressed Opinion on antimicrobial resistance genes in microbial products.  
 
VI-I-ii- B. licheniformis as a probiotic 
B. licheniformis is included in a product classified as a probiotic (ZooLac®, ChemVet 
DK AS, Denmark). ZooLac® is sometimes given to animals for the dietary 
management of digestion disorders. The total usage of ZooLac® in Norway in 2005 
was 776 litres paste (670 litres in 2004). We are not aware of any antimicrobial 
resistance property of the B. licheniformis used in Zoolac. 
VI-II- Bacitracin 
Bacitracin is a hexapeptide antibiotic, with a substituted thiazolidine nucleus, 
produced by some strains of B. licheniformis and Bacillus subtilis (Azevedo et al. 
1993). Six compounds have been detected, A, B, C, D, E, and F. Compound A 
represents about 70% of the complex. Bacitracin is a yellow-white powder, soluble in 
water and alcohol and insoluble in ether, chloroform, benzene, and acetone. 
Bacitracin is not absorbed in the gastrointestinal tractus and is degraded in the 
intestinal lumen. In infants, it is sometimes administered intramuscularly for the 
treatment of pneumonias. This formulation is sold under the brand name Baciim®. 
When applied locally (to the skin/mucous membrane), bacitracin is weakly absorbed. 
In Norway, bacitracin was formerly used as growth promoter in animal husbandry. 
For many years, bacitracin has been used in some topical preparations for human 
and veterinary medicine.  
VI-II-i- Mode of action 
Bacitracin is mainly active against Gram-positive bacteria, although many differences 
in susceptibility exist among the bacterial species (O'Grady and Greenwood 1997). 
The best characterized bactericidal effect of bacitracin is the inhibition of 
peptidoglycan biosynthesis (Storm 1974), but it may also interfere with additional 
cellular processes (Butaye et al. 2003).  
VI-II-ii- Bacitracin resistance among various bacterial species 
Despite its clinical importance, little is known about the mechanisms by which 
bacteria other than B. licheniformis acquire resistance to this antibiotic (Butaye et al. 
2003;Harel et al. 1999). 
Nevertheless, resistance mechanisms have been described for a few bacterial 
species including E. coli, B. subtilis, Streptococcus mutans and Enterococcus 
faecalis.  
VI-II-iii- Resistance to bacitracin in B. licheniformis  
For self-protection, B. licheniformis producer-strains are equipped with resistance 
mechanisms enabling them to combat the effects of their own metabolic products.  
An ABC transporter system (ATP-binding cassette) is considered to be the 
mechanism behind bacitracin resistance in B. licheniformis (Podlesek et al. 1995). 
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The transporter system, which has been proposed to mediate active efflux of 
bacitracin (Neumuller et al. 2001;Podlesek et al. 1995), is composed of two 
membrane-proteins, BcrB and BcrC, and two ATP-binding subunits, BcrA. In B. 
licheniformis, the bcrABC genes are localized about 3 kb downstream from the 
bacitracin biosynthesis operon bacABC (Neumuller et al. 2001). 
VI-II-iv- Known bacitracin resistance mechanisms in other bacterial 
species 
In E. coli, the bacA gene is involved in the synthesis of a lipid-carrier protein 
(undecaprenyl phosphate, C55-P) essential for peptidoglycan synthesis (El Ghachi et 
al. 2005). Bacitracin is known to block the synthesis and recycling of undecaprenyl 
phosphate by forming a complex with the precursor C55-PP. Over-expression of bacA 
is probably associated with a bacitracin-resistant phenotype in E. coli (Cain et al. 
1993). A different bacitracin resistance gene, bcrCec, encoding a homologue of the 
resistance gene in B. licheniformis, has also been described in E. coli (Harel et al. 
1999). 
In S. aureus and S. pneumoniae, genes homologous to the bacA gene have been 
found. It is unclear whether these genes play a role in acquired bacitracin resistance 
since they seem to be present in a wide variety of bacterial species, including 
bacitracin-susceptible ones. These genes might be related to the natural 
susceptibility level of these bacteria to bacitracin (Butaye et al. 2003). 
In B. subtilis, the bacitracin biosynthesis gene cluster from B. licheniformis, including 
the genes for self-protection, has been experimentally integrated into the 
chromosome. Synthesis of bacitracin was achieved at high level, as well as 
expression of the associated bacitracin self-resistance genes (Eppelmann et al. 
2001).  
Streptococcus mutans is naturally resistant to bacitracin. RGP (rhamnose-glucose 
polysaccharide)-synthesis has been shown to be related to bacitracin resistance in S. 
mutans through an unknown mechanism (Tsuda et al. 2002). 
Studies on bacitracin susceptibility and resistance among enterococci are limited, 
and a breakpoint for classification of resistant and susceptible isolates has not been 
determined. Detection and characterization of acquired genes encoding high-level 
bacitracin resistance in Enterocococcus faecalis has been reported (Manson et al. 
2004). The genes responsible for this resistance encode an ABC transporter system 
with some homology to the ABC transporter system present in B. licheniformis.  
VI-II-v- Unknown mechanisms  
In several bacterial genera, bacitracin resistance has been detected phenotypically, 
however the mechanisms of resistance remain unclear (Manson et al. 2004). 
Examples of such species are Clostridium perfringens (Devriese et al. 1993) and 
Streptococcus pyogenes (Mihaila-Amrouche et al. 2004).           
VI-II-vi- Resistance to antimicrobial agents in B. licheniformis  
Resistance to erythromycin and related antimicrobials is prevalent, but not universal, 
amongst strains of B. licheniformis (Docherty et al. 1981). This is also the case for 
strains deposited in culture collections before 1950, and thus before the widespread 
use of antimicrobials in human and veterinary medicine.  
Resistance against erythromycin in B. licheniformis is associated with the ermK or 
ermD gene  (Docherty et al. 1981;Kwak et al. 1991). The B. licheniformis producer 
strain used by Alpharma is reported to be resistant to bacitracin, sulfonamides and 
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erythromycin, although the method used for susceptibility testing is not in accordance 
to with standardized methodology. Resistance to erythromycin in this strain is 
mediated by the ermD gene. The presence of the ermD gene was detected by the 
use of hybridization with a specific probe (reported during meeting with 
representatives from Alpharma; 01.02.06).  We are not aware that ermD gene is 
transferable from B. licheniformis to other bacteria. 
The mechanism behind bacitracin resistance in B. licheniformis is due to the 
presence of a transporter system (ATP-binding cassette), as described above in 
section VI-III-iii. 
Resistance to sulfonamides is mediated by an unknown mechanism. The majority of 
the various Bacillus species are reported to be intrinsically resistant against 
sulfonamides  (2005).  
 
VI-II-vii- Occurrence of bacitracin resistance in Norway 
The Norwegian monitoring programme for antimicrobial resistance in bacteria from 
feed, food and animals (NORM-VET) has investigated resistance to bacitracin in E. 
faecalis and E. faecium between 2000-2004 (NORM-NORM-VET 2000;NORM-
NORM-VET 2001;NORM-NORM-VET 2002;NORM-NORM-VET 2003;NORM-
NORMVET 2004). Up to 50% of the investigated isolates have been reported as 
resistant against bacitracin. However, the determination of the in vitro activity of 
bacitracin has been bedevilled by a lack of standardized reference methodology, a 
lack of agreement on interpretive criteria such as breakpoints, and by lack of any 
great interest in this antibiotic, particularly in human medicine.     
Resistance to bacitracin in human pathogens is not investigated in the Norwegian 
monitoring programme for antimicrobial resistance (NORM). However, reduced 
susceptibility to bacitracin among S. pyogenes, and S. aureus isolates of human 
origin has been recognized in Norway (Arne Høiby, Norwegian Institute of Public 
Health, personal communication). 
 
VI-III- Possible dissemination of antimicrobial resistance genes 
from the B. licheniformis producer strain to environmental bacteria 
The B. licheniformis 20443 strain used by Alpharma to produce bacitracin is highly 
resistant to bacitracin and sulfonamide, and to a lesser degree erythromycin. The 
proposed composting of waste from Alpharma’s bacitracin production implies that live 
bacteria and naked DNA present in the waste will come into close contact with 
environmental bacteria during the composting process. Consequently, the possibility 
exists that bacitracin, sulfonamide and erythromycin resistance genes can be 
transferred to the endogenous population of bacilli and other soil bacteria (e.g. 
enterococci).  
Bacteria use three major mechanisms for horizontal gene transfer: conjugation, 
transduction and natural genetic transformation. Conjugation and transduction are 
common among bacteria, because they depend on ubiquitous elements such as 
plasmids, transposons and bacteriophages. Conjugation and transduction require 
that donor bacteria are alive, whereas horizontal gene transfer by natural 
transformation depends on naked DNA released from dead donor bacteria. More 
than 50 different bacterial species have so far been shown to be competent for 
natural genetic transformation. Among these are the soil bacterium B.subtilis and 
some isolates of B.licheniformis (Lorenz and Wackernagel 1994;Rey et al. 
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2004;Spizizen and Prestidge 1969). Although competence for natural transformation 
has never been demonstrated in Bacillus cereus or Bacillus anthracis under 
laboratory conditions, their genome sequences contain homologues of B. subtilis 
competence genes, indicating that natural genetic transformation actually occurs in 
these bacteria under natural conditions (Vilas-Boas et al. 2002).  
VII- Exposure assessment 
VII-I- B. licheniformis 
VI-I-i- Ecology 
Due to the resistance of their endospores to environmental stresses, as well as their 
long-term survival under adverse conditions, B. licheniformis is ubiquitous and can be 
isolated from a wide variety of sources. Hence, the occurrence of B. licheniformis in a 
certain environment is not necessarily an indication of habitat and it is generally 
accepted that the primary habitat is the soil. In the soil environment B. licheniformis 
become metabolically active when suitable substrates for growth are available, and 
presumably form spores when nutrients are exhausted. This is a strategy used by 
other microbes in the soil habitat, including the filamentous fungi and the 
actinomycetes, which also form resting structures (spores), and produce antibiotics in 
association with their sporulation process.  
 
Since most Bacillus species can effectively degrade a series of biopolymers 
(proteins, starch, pectin, etc.), they are assumed to play a significant role in the 
biological cycles of carbon and nitrogen.  
From soil, by direct contact, or by air-borne dust, Bacillus spores can contaminate 
just about anything that is not maintained in a sterile environment. They may also 
play a biodegradative role in whatever they contaminate, and thereby they may be 
agents of unwanted decomposition and decay. Several Bacillus species are 
especially important as food spoilage organisms (e.g. B. cereus). 
 
The bacterium is likely to enter the human and animal digestive system many times a 
day (U.S.Environmental Protection Agency 1997). Data regarding its ability to survive 
in the gastrointestinal tract are sparse; however, it is highly likely that the spores will 
pass through without causing harm. Outside the gastrointestinal tract, the bacterium 
can be a temporary colonizer of skin.  
VII-I-ii-Prevalence of B. licheniformis in compost 
Various investigations have shown that many different types of thermophilic bacteria 
are involved in decomposing protein and other readily degradable organic matter 
(Ichida et al. 2001;Wehner et al. 2002;Zhang et al. 2002). They appear to be 
responsible for the intense activity characteristic of the first few days, when 
temperatures reach 65° to 70 °C. Thermophilic species belonging to the genus 
Bacillus are very common in both thermogenic, post-thermogenic and final compost 
samples, e.g. Bacillus thermodenitrificans, B. licheniformis, B. macerans and B. 
stearothermophilus. Viable cell numbers range from 1.5 to 150 × 106 colony forming 
units per gram compost (wet weight), with the highest counts being from samples 
with temperatures of 70 °C and 55 °C. In one study (Zhang et al. 2002), B. 
thermodenitrificans was the dominant isolate (representing more than 50% of isolates 
from total plate counts) in 7 of the 11 individual compost total plate count samples 
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between 30 °C to 73 °C, and accounted for 68.9% of all isolates. B. licheniformis 
accounted for 7.2% of all isolates and was the dominant isolate in one sample. 
VII-I-iii- B. licheniformis 20443 in compost produced from waste 
The waste product from the bacitracin production, which is designated “slurry” and is 
mixed with bark chips and lime and subjected to composting, contains 104-105 total 
colony counts per gram. Due to methodological limitations, the fraction of B. 
licheniformis 20443 cells was not determined, but the slurry may contain between 
102-103/g living 20443 cells. Viable spore counts in the slurry were less than 10 
spores /ml. There was a lower total cell count in composted slurry than in composted 
sludge and composted household waste. However, the composted slurry was older 
than the other compost types. Numbers of viable spores were about the same. The 
dominant Bacillus spp. present in soil and compost were tentatively assigned to the 
Bacillus cereus group (information and data delivered by Alpharma AS and Lindum 
AS).  
VII-II- Concentration of bacitracin in compost and soil 
According to the most recent estimates using LC-MS analysis, composted waste 
from Alpharma contains 345 ppm bacitracin after 3 days, 31 ppm after 7 days and 
about 3 ppm after 25 days. Based on “spiking” of compost with a known amount of 
bacitracin and subsequent extraction by a mixture of methanol, water, and acetic acid 
(90:9:1), recovery of bacitracin was estimated to be in the range of 50-70%.  
Annual waste production is about 1400 metric tons (30 % dry weight). This may 
amount to 1500-2000 metric tons (dry weight) of finished compost including bulking 
agents (due to the liquid character of the waste, large quantities of bark or suitable 
bulking material have to be added). A maximum of 40 metric tons compost per 
hectare of agricultural land is allowed for quality class I compost products over a 10-
year period. Thus, annual application of 1600 metric tons of compost to agricultural 
soil requires 400 hectares of available farmland. As the compost contained 3 mg 
bacitracin per kg after 25 days, if a content of 1 mg per kg at the time of application is 
assumed this corresponds to 40 grams per hectare or about 10-15 µg per kg soil 
(about 100 µg per litre soil water).  
VII-III- Exposure to antimicrobial resistance genes 
Clearly, the amount of bacitracin present during the first week of compost 
fermentation (see paragraph above) is sufficient to exert a selection pressure on the 
susceptible members of the bacterial population. Consequently, conditions that 
promote dissemination of bacitracin resistance genes to natural strains will prevail for 
a considerable period of time. Presumably, significant amounts of free DNA from B. 
licheniformis 20443 will be present in the waste material used for compost production 
(see data gaps section). This DNA may be taken up by naturally competent bacilli 
present during the first week of fermentation. Therefore, conditions promoting the 
dissemination of bacitracin resistance genes seem to be present during the first week 
of compost fermentation.  
However, in the absence of a corresponding selection pressure, dissemination of 
sulfonamide and erythromycin resistance genes from the B. licheniformis producer 
strain is unlikely to exceed background level, i.e. the level of naturally occurring gene 
transfer in soil. 
According to a study from Danish Research Centre for Organic Farming 
(www.darcof.dk/enews/june04/gmo.html) composting of transgenic plant material has 
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indicated that DNA is degraded much faster than structural plant material, and DNA 
could no longer be detected after 14 days when the temperature peaked at 58 oC. At 
higher temperatures DNA disappeared after 6 days. In soil, transgenic DNA could still 
be detected after 77 days (Magid et al. 2004). These experiments showed that 
composting of GM plant residues greatly increases the rate of degradation of 
transgenic DNA compared to the rate for plant residues left in the soil. However, 
despite these observations, it cannot be concluded that horizontal gene transfer 
cannot take place. 
In general, the presence and fate of antimicrobial resistance genes in compost has 
rarely been assessed. In a compost preparation produced from a horse-bedding 
straw-deep-litter chicken manure mixture supplemented with gypsum, background 
resistance of the compost microflora to selective agents (kanamycin, novobiocin, 
tetracycline, thiostrepton, and NaCI) was demonstrated to be extremely varied 
(Amner et al. 1988). Real-time PCR assays may provide rapid, quantitative 
cultivation-independent measurements of resistance genes. The utility of real-time 
PCR assays has recently been demonstrated by quantifying three tetracycline 
resistance (tet) gene groups present in bovine and swine manures, composts of 
swine manure, lagoons of hog house effluent, and samples from an Ekokan upflow 
biofilter system treating hog house effluent (Yu et al. 2005). The bovine manures 
were found to contain fewer copies of all three groups of tet genes than the swine 
manures. Composting of swine manures substantially reduced tet gene abundance 
(by up to 6 logs), while lagoon storage or the upflow biofilter had little effect on tet 
gene abundance. In cases where the antimicrobials are rapidly degraded, these 
results suggest that composting may have a substantial impact on the persistence 
and dissemination of resistance genes that have no other selective advantage. 
VII-IV- Use of bacitracin in Norway 
Two preparations containing bacitracin are registered for use in Norway (Bacimycin® 
powder and Bacimycin® ointment).  
In Norway, the usage in 2005 was 400 kg powder and 1800 kg ointment.  
This corresponds to 1000 million IU (International Unit) bacitracin (Hege Salvesen 
Blix, personal communication). The same preparation is used in both human and 
veterinary medicine. Bacitracin has not been used as a feed additive for domestic 
animals in Norway since 1997(NORM-NORMVET 2004).  
According to the Norwegian monitoring programme for antimicrobial resistance in 
bacteria from humans (NORM), a marked increase in isolation frequencies of fusidic 
acid resistant S. aureus associated with impetigo bullosa among children has been 
recognized. The Norwegian monitoring programme for antimicrobial resistance in 
bacteria from feed, food and animals (NORM-NORM-VET 2000;NORM-NORM-VET 
2001;NORM-NORM-VET 2002;NORM-NORM-VET 2003;NORM-NORMVET 2004)     
has registered the same tendency regarding the occurrence of fusidic acid resistant 
staphylococci isolated from animals.Therefore, bacitracin has been suggested as one 
of the drugs of choice for treatment of impetigo in Norway.  
 
VIII- Risk characterization 
VIII-I- Survival of B. licheniformis 20443 bacitracin producer strain 
Experiments conducted by Alpharma indicate that the production strain accounted for 
less than 1% of all compost isolates. Most isolates belonging to the genus Bacillus, 
Norwegian Scientific Committee for Food Safety 05-106-Final 
 13 
were assigned to the B. cereus group. If this is correct, the production strain may 
differ substantially from the range of phenotypes exhibited within the species and 
apparently displays a selective disadvantage compared to the original strain when 
reintroduced to soil.  
VIII-II- Bacitracin 
In the spiking experiment, bacitracin was allowed to stay in contact with the solid 
phase of the compost for only 20 min before extraction. In our opinion, this period 
may have been too short for bacitracin to penetrate into the micropores in the solid-
phase material, and for bactracin to form stable non-covalent complexes with the 
solid phase. It is therefore possible that the estimated recovery is too high and not 
applicable to the situation where bacitracin has stayed in contact with the solid-phase 
for a longer period. However, low recovery may indicate less bioavailability and 
reduced selection pressure. Regardless of recovery, sufficient residual bacitracin is 
present in the initial phase of the composting process to exert a selection pressure 
that promotes dissemination of bacitracin resistance genes. Residual bacitracin in the 
final product is low and less likely, if at all, to promote selective advantage to 
resistant soil or compost bacteria. 
 
VIII-III- Propagation of antimicrobial resistance from the B. 
licheniformis 20443 bacitracin producer strain 
Undoubtedly antimicrobial resistance genes will be transferred from the B. 
licheniformis bacitracin producer strain to members of the genus Bacillus and other 
bacteria present in the compost environment, if compost containing the producer 
strain is mixed with soil. Studies on agricultural soil treated with animal waste, and 
laboratory experiments carried out using soil microcosms, support this view, but the 
efficiency of  the gene transfer processes in soil is believed to be relatively low 
(Graham and Istock 1979;Jensen et al. 2001;Lorenz and Wackernagel 1994). 
Consequently, without a selection pressure promoting the survival and propagation of 
soil bacteria that have acquired antimicrobial resistance genes from the B. 
licheniformis producer strain, the number of transformants present in the enriched 
soil environment will be very small. In contrast, in environments where bacitracin, 
sulfonamide, or erythromycin is present at concentrations affecting bacterial growth, 
bacteria acquiring antimicrobial resistance by incorporating resistance determinants 
from the B. licheniformis producer strain will have a selective advantage and 
potentially reach high numbers. 
As resistance to sulfonamide, and erythromycin is common among B licheniformis  
(Docherty et al. 1981) and other soil bacteria (D'Costa et al. 2006), the presence of a 
low number of B. licheniformis 20443 cells carrying these determinants is not 
considered to present a significant risk to human health or the environment. 
 
IX- Data gaps 
During the preparation of this assessment, the following data gaps were identified: 
• Insufficient documentation on the number of surviving Bacillus licheniformis 
20443 cells present in the compost after fermentation. 
• No information on the amount of free DNA from Bacillus licheniformis 20443 
present in the waste material used for compost production. 
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• Lack of use of simple molecular typing tools (like Random  
Amplification of Polymorphic DNA; RAPD) to differentiate between the B. 
licheniformis production strain 20443 and other B. licheniformis present in 
compost/soil. 
• Lack of information on the occurrence and presence of pathogenic bacteria 
(e.g. enterococci) in the composting system. 
• The extent to which the resistance genes in B. licheniformis are transferable 
and can mediate phenotypically-expressed resistance in other bacterial 
species, like human and animal pathogens, is not documented. 
• An absence of a standardized method to determine bactericidal and 
bacteriostatic (Minimum Inhibitory Concentration, MIC) values for bacitracin. 
 
X- Answers to the questions 
1- Assessment of risk in relation to residual content of bacitracin in the 
finished product. 
Will the residual content of bacitracin in the proposed compost pose any risk 
to human health or the environment? 
 
According to the measurements conducted and presented by Alpharma, after the 
production waste has been mixed with bark chips and lime and composted for 25 
days, the concentration of bacitracin is about 3 ppm or less. It is highly unlikely that 
bacitracin at this concentration will pose a significant risk to human health or have 
adverse toxicological effects. However the antibiotic may exert a selection pressure 
on the bacterial community in the compost (see below), and thus a possible long-
term effect cannot be excluded.   
 
2- Assessment of risk in relation to dissemination of the production strain  
 
a- Assess the risks of disseminating B. lichenformis 20443 to the environment, 
and whether such dissemination could pose a threat to human health or the 
environment?  
It is likely that B. licheniformis 20443, which is the laboratory mutant strain used by 
Alpharma to produce bacitracin, has lost some of its ability to compete with bacteria 
found in the environment. The 20443 strain does not form spores during the 
production process, and due to the low pH (pH 4.0) relatively few living bacteria (102-
103 cfu/g) are present in the waste used for composting. Furthermore, studies carried 
out by Alpharma suggest further reductions in strain 20443 in the waste product 
during the composting process. However, more accurate data are required to confirm 
these findings. Considering the low number of producer bacteria remaining in the 
finished product, the probability is low that it will disseminate from the compost. 
Consequently, because B. licheniformis appears to be essentially non-pathogenic to 
healthy people, and very uncommon as an opportunistic pathogen in humans, the 
bacterium constitutes a minimal risk to human health or the environment.  
The situation will differ if sufficient bacitracin is present in the compost to inhibit 
growth of a significant fraction of the natural population. This scenario is unlikely, 
however, as a concentration of about 3 ppm bacitracin will probably be too low to 
exert sufficient effective selection pressure to enable the bacitracin-resistant 
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producer strain to out-compete other bacteria. Additionally, only Gram-positive 
bacteria are susceptible to bacitracin.  
 
b- Assess the risks of dissemination of antibiotic resistance genes from the 
compost. 
 
The waste product designated “slurry”, which is mixed with bark chips and lime and 
subjected to composting, contains relatively high amounts of bacitracin. In addition 
this slurry may contain 102-103 living B. licheniformis 20443 cells per gram plus 
unknown amounts of free DNA released from dead and disintegrated producer 
bacteria. Consequently, it is likely that during the first week of composting, selection 
pressure will favour the transfer of bacitracin-resistance genes to different strains and 
species of Bacillus and possibly other species growing in the compost. It is not 
possible to predict the extent of such lateral gene transfer, but it is reasonable to 
assume that under the special conditions prevailing early in the composting process, 
increased dissemination of the bacitracin-resistance genes to the environment may 
take place relative to background level. However, this is considered to represent a 
low risk to human health and the environment.  
The abundance of resistance genes in the finished compost will probably be close to 
the background level and application of the final product as a soil amendment will not 
contribute to increased dissemination of bacitracin-resistance. However, this is 
considered to represent a low risk to human health and the environment.  
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